51 related articles for article (PubMed ID: 16786333)
41. [Clinical benefit of S-1 in metastatic breast cancer].
Saeki T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():202-6. PubMed ID: 16898003
[TBL] [Abstract][Full Text] [Related]
42. [S-1 combined with weekly paclitaxel in patients with advanced gastric cancer].
Gotoh M; Kawabe S; Takiuchi H
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():91-4. PubMed ID: 16897980
[TBL] [Abstract][Full Text] [Related]
43. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
[TBL] [Abstract][Full Text] [Related]
44. S-1 as a core anticancer fluoropyrimidine agent.
Miura K; Shirasaka T; Yamaue H; Sasaki I
Expert Opin Drug Deliv; 2012 Mar; 9(3):273-86. PubMed ID: 22235991
[TBL] [Abstract][Full Text] [Related]
45. A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity.
Seymour L; Eisenhauer E
Cancer Chemother Pharmacol; 2001; 47(1):2-10. PubMed ID: 11221956
[TBL] [Abstract][Full Text] [Related]
46. Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Fujita K; Sasaki Y
Drug Metab Pharmacokinet; 2014; 29(1):20-8. PubMed ID: 24256625
[TBL] [Abstract][Full Text] [Related]
47. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
[TBL] [Abstract][Full Text] [Related]
48. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
49. [Combination chemotherapy of TS-1 +cisplatin for inoperable gastric cancer].
Koizumi W; Tanabe S; Higuchi K; Sasaki T; Nakayama N; Nagaba S; Azuma M; Shimoda T; Nishimura K; Nakatani K; Saigenji K
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1957-61. PubMed ID: 15570920
[TBL] [Abstract][Full Text] [Related]
50. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma.
Ajani JA
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():117-20. PubMed ID: 16897985
[TBL] [Abstract][Full Text] [Related]
51. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]